High Dose SPINRAZA EU Approval Might Change The Case For Investing In Biogen BIIB
January 28, 2026
QuantWave Achieves 16.13% Profit Target with Biogen Inc. Forecast
October 3, 2025
Biogen Inc. Hits Price Target Forecast, Yielding 13.66% Profit for QuantWave Users
October 3, 2025
Biogen Inc. Stock Hits Forecast Price Target with an 11.55% Profit – A Success for QuantWave's Analytics
October 3, 2025
Biogen Inc. Stock Hits Forecast Price Target with 10.37% Profit as Predicted by QuantWave
October 3, 2025
Biogen Inc. Hits Price Target Forecast with an 11.17% Profit Margin
October 3, 2025
Biogen Inc.: Revolutionizing Healthcare with Innovative Biotechnology
January 2, 2025
Biogen Inc Announces Strong EPS Growth in Q4 2024 Earnings Call
February 20, 2025
Biogen Inc. Continues to be a Top Value Stock for Long-Term Investors
January 1, 2025
Stifel downgrades Biogen on slow Alzheimer's drug launch uncertainty ahead
December 22, 2024
Biogen Inc.: A Promising Investment for the Future of Healthcare Stocks
January 2, 2025
Investor opinions & comments
To leave a comment, you need to Login or Register.
FinanceFlo
February 8, 2026 at 14:43
This is fantastic news! Biogen's dedication to research and innovation is truly impressive
MaryJohnson
February 7, 2026 at 08:22
I'm not sure about the long-term benefits of Biogen's research. More data and studies are needed to assess the true impact of their innovations
KevinWalker
February 7, 2026 at 01:55
Biogen's groundbreaking work in neurology and immunology is truly inspiring. They are leading the way in the biotechnology sector